Table 3.

Multivariate analysis of overall survival in cohort 2 (ipilimumab + nivolumab)

				Model 1			Model 2
Factor	N	%	% Dead	HR	95% CI	P	HR	95% CI	P
S100B
≤0.3 µg/l	57	66.3	22.8	1			1
>0.3 µg/l	29	33.7	72.4	6.97	2.87–16.89	<0.0001	7.29	2.97–17.89	<0.0001
LDH
≤1.5xULN	61	70.9	31.1	1			1
>1.5xULN	25	29.1	60.0	1.29	0.58–2.86	0.53	1.22	0.55–2.73	0.63
Visceral metastasis
No	14	16.3	28.6	1			1
Yes	72	83.7	41.7	0.98	0.33–2.95	0.97	0.76	0.24–2.42	0.64
CNS metastasis
No	61	70.9	36.1				1
Yes	25	29.1	48.0				1.82	0.81–4.09	0.15
Origin
Cutaneous	59	68.6	35.6	1			1
Occult	16	18.6	50.0	2.74	1.00–7.53	0.051	3.02	1.10–8.26	0.032
Mucosal	4	4.7	75.0	1.08	0.30–3.83	0.91	0.82	0.21–3.10	0.77
Uveal	7	8.1	28.6	2.07	0.41–10.56	0.38	2.65	0.50–14.15	0.25

CI confidence interval, CNS central nervous system, HR hazard ratio, LDH lactate dehydrogenase, N number of patients, P P-value